Treating Aging-Related Disease by Targeting Molecular Drivers of Aging

Episode Summary

Executive Summary: BioAge CEO Kristen Fortney describes how the company uses human aging cohorts, multi-omics, and AI to identify aging pathways that predict disease, then advances therapies aimed at preserving healthspan. The conversation highlights BioAge’s lead muscle-atrophy program, NLRP-3 inflammasome work for neuroinflammation, and the company’s bet that human data can de-risk targets and reveal new ones.

Main Topics: Aging as a driver of disease (Priority: 5/5): Fortney argues aging is not just a condition but the underlying process that predisposes people to major chronic diseases, making it a rational intervention point for drug discovery. Human data and BioAge’s discovery platform (Priority: 5/5): BioAge uses long-term biobank cohorts, electronic health records, and multi-omics to connect midlife biology with later-life healthspan, leveraging human evidence to guide target selection. BGE-105 and muscle preservation (Priority: 5/5): The company’s most advanced candidate targets APJ/apelin signaling to prevent muscle loss, with programs in ICU-related atrophy and GLP-1-associated lean mass loss. NLRP-3 inflammasome and neuroinflammation (Priority: 4/5): BioAge is developing NLRP-3 inhibitors for CNS and ocular diseases, emphasizing the link between inflammatory signaling in midlife and future cognitive decline. Why human validation matters (Priority: 4/5): Fortney contrasts BioAge’s approach with traditional mouse-first discovery, arguing that lifetime human association data improve translational confidence and safety assessment. Pipeline breadth and future target discovery (Priority: 3/5): The discussion closes on the broader promise that aging biology may yield both broadly applicable targets and novel mechanisms not yet seen in animal models.

Key Arguments: Aging should be viewed as a fundamental upstream driver of many diseases rather than only an inevitable process, because intervening in aging pathways may reduce risk across multiple chronic conditions. Human cohorts with decades of follow-up provide rare evidence linking midlife biomarkers to later disease, healthspan, muscle function, and cognition, making target selection more translationally robust. APJ/apelin signaling emerged from BioAge’s datasets as predictive of better lifespan, cognitive outcomes, and muscle outcomes, supporting BGE-105 as a muscle-preserving therapy. BioAge’s preclinical and early clinical studies suggest BGE-105 can prevent muscle atrophy in both animal models and older bed-rested volunteers, supporting development in ICU and obesity-related lean mass loss. NLRP-3 inflammasome activity in midlife is strongly associated with future cognitive decline, making it a plausible target for brain-related aging diseases. Even if some aging pathways have normal roles earlier in life, BioAge believes their activity later in life becomes maladaptive and therapeutically addressable. Human data serve two purposes: validating known aging mechanisms in humans and uncovering novel targets that may not appear in mouse studies. The company believes its current funding is sufficient to advance programs to key milestones over the next couple of years.

Data Points: Human longevity prevalence: ~1 in 1,000 in the United States reach age 100 - Fortney cites this as inspiration for studying exceptionally healthy aging trajectories Mouse muscle atrophy protection: Close to 50% decrease in muscle weight prevented - In a very old mouse cast model, BGE-105 nearly fully protected against rapid atrophy Bed-rest study duration: 10 days - Older volunteers were kept in bed to model aging-related muscle atrophy Bed-rest participant age: Average low 70s - Phase 1b human study of BGE-105 in older volunteers Mechanically ventilated patients: Close to 5 million per year - Population targeted for ICU diaphragm atrophy indication Diaphragm atrophy incidence: About half - Roughly half of mechanically ventilated patients develop clinically meaningful diaphragmatic atrophy within days Diaphragm thinning threshold: 10% or more decrease in thickness - Ultrasound-measured marker of clinically meaningful diaphragmatic atrophy Diaphragm atrophy time course: 3 to 4 days - How quickly severe diaphragmatic atrophy can occur in ventilated patients Lean mass loss on GLP-1s: Up to half of weight loss - Motivating BioAge’s combination strategy with BGE-105 to preserve muscle Funding raised: More than $100 million - Total capital BioAge has raised to date Expected runway: Till end of next year and till data - Fortney says current funding should carry the company through key milestones

Pivotal Quotes: "aging itself is such an important driver of disease, by looking at disease through the lens of aging, we're going to discover important new targets" — Kristen Fortney: Explaining BioAge’s core thesis for target discovery "if you have elevated apolin for decades, that only seems to associate with good outcomes, with improved muscle function, with improved cognitive function" — Kristen Fortney: Justifying the APJ/apelin pathway as a protective human signal "the biggest value of human data is that it's very translationally de-risking" — Kristen Fortney: Answering why BioAge prioritizes human cohort evidence over mouse-only findings

Implications: BioAge’s strategy suggests aging biology may become a broad drug-discovery engine, especially for muscle, cognition, and inflammation. If human-cohort validation keeps translating, it could reshape how biotech prioritizes targets and combination therapies.